MétaCan
Menu
← Back to cohort
Record W2623711786 · doi:10.1002/hon.2437_11

CVP OR R‐CVP GIVEN AFTER INVOLVED‐FIELD RADIOTHERAPY IMPROVES PROGRESSION FREE SURVIVAL IN STAGE I‐II FOLLICULAR LYMPHOMA: RESULTS OF AN INTERNATIONAL RANDOMIZED TRIAL

2017· article· en· W2623711786 on OpenAlexaffabout
Michael MacManus, Richard Fisher, Daniel Roos, Peter C. O’Brien, Andrew Macann, Richard Tsang, Susan R. Davis, David Christie, Bev McClure, David Joseph, John F. Seymour

Bibliographic record

VenueHematological Oncology · 2017
Typearticle
Languageen
FieldMedicine
TopicLymphoma Diagnosis and Treatment
Canadian institutionsPrincess Margaret Cancer Centre
Fundersnot available
KeywordsMedicineRituximabVincristineRandomized controlled trialProgression-free survivalFollicular lymphomaInternal medicineSurgeryRadiation therapyStage (stratigraphy)GastroenterologyCyclophosphamideLymphomaChemotherapy

Abstract

fetched live from OpenAlex

Aim: Curative-intent involved field radiation therapy (IFRT) is a standard treatment for stage I-II follicular lymphoma (FL). It achieves durable local disease control and can produce life-long remissions. However ≥50% of patients relapse, generally outside irradiated volumes. We conducted a randomized controlled trial (RCT) to determine if systemic therapy could improve progression free survival (PFS). Patients and Methods: Patients from Australia, New Zealand and Canada with stage I-II FL of grade 1, 2 or 3a were enrolled after mandatory CT scans and marrow biopsies. PET staging was permitted. Patients were randomized to either; Arm A: 30Gy IFRT alone or Arm B: IFRT followed by 6 cycles of cyclophosphamide 1000 mg/m2 IV D1, vincristine 1.4 mg/m2 D1 and prednisolone 50 mg/m2 D1-5 (CVP), stratified by center, stage, age and PET. A protocol amendment in 2006 added Rituximab 375 mg/m2 D1 to arm B (R-CVP). Results: Between February 2000 and July 2012, 150 patients were recruited: 75 per arm: 44 arm B patients were allocated CVP and 31 R-CVP. Median age was 57 (range 30-79) years, 52% were male, 75% had stage 1 and 48% were PET-staged. Only 8% had an extranodal site (ENS). Median potential follow-up was 9.6 years (range, 3.1-15.8). PFS was significantly superior for arm B (IFRT + systemic therapy) compared to arm A [HR 0.57 (0.34-0.95); p = 0.033]. At 10 years PFS was 58% (95% CI 46-74%) for arm B and 41% (95% CI 30-57%) for arm A. Patients randomized to R-CVP had a substantially superior PFS to those contemporaneously randomized to IFRT alone, [HR 0.26 (0.07-0.97); p = 0.045]. In univariate analysis, patients who had ENS (p = 0.02), fewer involved regions (p = 0.047) and PET staging (p = 0.056) also had improved PFS. Transformation to high-grade lymphoma occurred in 4 patients in arm B compared to 10 in arm A (p = 0.1). Overall survival (OS) is not currently significantly different between arms (HR 0.62, p = 0.4); 10 year rates 95 vs 87% for arms B and A respectively. Only 2 patients had isolated in-field relapses, therefore systemic therapy primarily prevented progression outside RT fields. Only 3 cases with grade 3-4 acute and 1 case with grade 3 late radiation toxicities were observed. Systemic therapy was associated with 29 cases of grade 3 toxicity and one of grade 4 (neuropathy). One treatment-associated death occurred per arm. Keywords: Chemotherapy; follicular lymphoma (FL); rituximab.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.004
metaresearch head score (Gemma)0.004
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.006
Threshold uncertainty score0.019

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0040.004
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0030.003
Bibliometrics0.0000.001
Science and technology studies0.0000.001
Scholarly communication0.0010.001
Open science0.0010.000
Research integrity0.0020.003
Insufficient payload (model declined to judge)0.0060.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.036
GPT teacher head0.372
Teacher spread0.336 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations6
Published2017
Admission routes2
Has abstractyes

Explore more

Same venueHematological Oncology→Same topicLymphoma Diagnosis and Treatment→French-language works237,207→